Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio will share new Phase 2a alopecia areata data for bempikibart at EADV 2026, with materials posted online afterward.

Rhea-AI Summary

Q32 Bio (QTTB) will present late-breaking 36-week and initial 16-week off-drug results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart in severe or very severe alopecia areata at the European Academy of Dermatology and Venereology Congress 2026 in Vienna, Austria, held September 30 – October 3, 2026.

Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling. An oral late-breaking presentation (Abstract LB-375) on September 30, 2026 at 3:15 p.m. CEST in Hall A and a poster session (Abstract AS-726) on the same day at 7:00 a.m. CEST in the Poster Area will both be delivered by Arash Mostaghimi of Brigham and Women's Hospital and Harvard Medical School. The company plans to post these materials in the “Presentations and Publications” section of its website after the formal EADV presentations.

Key Figures

Additional results period: 36 weeks Off-drug period: 16 weeks Congress dates: September 30–October 3, 2026

Additional results period

36 weeks

SIGNAL-AA Part B

Off-drug period

16 weeks

Initial findings from SIGNAL-AA Part B

Congress dates

September 30–October 3, 2026

EADV Congress in Vienna, Austria

Key Terms

anti-il-7rα antibody, phase 2a, off-drug period, tslp signaling

4 terms

anti-il-7rα antibody medical

"Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate"

A monoclonal antibody that binds the alpha chain of the interleukin‑7 receptor (IL‑7Rα) on immune cells, blocking IL‑7 signaling that helps certain white blood cells grow and survive. Think of it like a key that fits the receptor’s lock to shut off a specific immune signal; it matters to investors because such drugs are studied as treatments for autoimmune diseases and some cancers and can drive clinical, regulatory, and commercial value.

phase 2a medical

"Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

off-drug period medical

"initial findings from the 16-week off-drug period from Part B"

A planned stretches of time when a clinical trial participant stops taking the investigational drug so researchers can observe how the body behaves without the medication or allow the drug to clear from the system. Like pausing background music to hear a single instrument, an off-drug period helps separate drug effects from other factors and is important to investors because it affects how cleanly safety and efficacy results are measured and how regulators will view the data.

tslp signaling medical

"by blocking IL-7 and TSLP signaling"

A biological process in which the protein thymic stromal lymphopoietin (TSLP) binds its receptor on immune cells and triggers a chain of molecular signals inside those cells, altering their behavior and promoting inflammation or allergic responses. Investors care because drugs that block or modify TSLP signaling are a target for therapies in asthma, eczema and other immune conditions, so changes in clinical trial results, regulatory decisions, or patent news about this pathway can affect a drug’s commercial prospects much like a key ingredient determining a recipe’s success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in alopecia areata --

WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA will be featured across late-breaking oral and poster presentations at the European Academy of Dermatology and Venereology ("EADV") Congress, taking place September 30 – October 3, 2026 in Vienna, Austria. Bempikibart is a fully human anti-IL-7Rα antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling.

"Our late-breaking oral and poster presentations highlighting additional 36-week results as well as initial findings from the 16-week off-drug period from Part B of SIGNAL-AA underscores our commitment to bringing a differentiated, targeted therapeutic to patients with alopecia areata in need of new treatment options and the growing enthusiasm for bempikibart's unique mechanism in the field," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "This recognition reinforces our conviction in our bempikibart development program in alopecia areata, as well as its potential in other autoimmune and inflammatory conditions, and we look forward to sharing our results with the scientific community."

The oral presentation details are as follows:

• Title: Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial
• Abstract Number: LB-375
• Session: D1T01.1 – Late Breaking News
• Presenter: Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital, Harvard Medical School
• Date and Time: Wednesday, September 30, 2026, 3:15 p.m. CEST / 9:15 a.m. EST
• Location: Hall A

The poster presentation details are as follows:

• Title: Preliminary Results for an Open-label Phase 2a Trial (SIGNAL-AA Part B) of Bempikibart, a Novel IL-7Rα Antibody in Patients with Severe or Very Severe Alopecia Areata (AA)
• Abstract Number: AS-726
• Session: Biologics, immunotherapy, targeted therapy
• Presenter: Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation, Brigham and Women's Hospital, Harvard Medical School
• Date and Time: Wednesday, September 30, 2026, 7:00 a.m. CEST / 1:00 a.m. EST
• Location: Poster Area

The presentations will be available in the "Presentations and Publications" section of the Q32 Bio website following the formal EADV presentation.

About Q32 Bio

Q32 Bio is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata¹, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.

¹National Alopecia Areata Foundation

Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements contained herein which do not describe historical facts are forward-looking statements, including, among others, Q32 Bio's beliefs, observations, expectations and assumptions regarding additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial and the anticipated timing of its data, the safety, tolerability, clinical activity including biomarker data, potential efficacy and potential benefits of bempikibart including plans and expectations for Part B of the SIGNAL-AA Phase 2a clinical trial,  the expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of Q32 Bio's product candidates, including bempikibart, and anticipated milestones, and Q32 Bio's beliefs, expectations and assumptions regarding the future of its business, future plans and strategies; which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Forward-looking statements are based on management's current beliefs and assumptions, which are subject to risks and uncertainties and are not guarantees of future performance. Such risks and uncertainties include, among others, the risk that additional data, or the results of ongoing data analyses, may not support Q32 Bio's current beliefs and expectations for bempikibart, including with respect to the durability of clinical responses, the risk that ongoing and future clinical studies might be more costly than expected or might not yield anticipated results, that Q32 Bio may use its capital resources sooner than currently anticipated, our expectations regarding the sufficiency of our cash and cash equivalents to provide financial runway and that we may need additional funding to complete clinical studies, which may not be available on favorable terms or at all and such other risks and uncertainties identified in Q32 Bio's periodic, current and other filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequent filings with the SEC, which are available at the SEC's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect Q32 Bio's results of operations and its cash flows, which would, in turn, have a significant and adverse impact on Q32 Bio's stock price. Q32 Bio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Q32 Bio disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Contacts

Investors: Brendan Burns
Senior Director, Investor Relations and Corporate Communications
Q32 Bio
bburns@q32bio.com

Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-announces-upcoming-late-breaking-presentation-of-results-from-part-b-of-the-signal-aa-clinical-trial-of-bempikibart-in-alopecia-areata-at-the-european-academy-of-dermatology-and-venereology-congress-2026-302884741.html

SOURCE Q32 Bio

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What specific aspects of the SIGNAL-AA Part B trial will be highlighted at EADV 2026?

The EADV late-breaking oral and poster presentations will feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the Phase 2a SIGNAL-AA trial evaluating bempikibart in patients with severe or very severe alopecia areata.

When and where is the oral presentation on bempikibart scheduled during EADV 2026?

The oral presentation, titled “Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial” (Abstract LB-375), is scheduled for Wednesday, September 30, 2026, at 3:15 p.m. CEST / 9:15 a.m. EST in Hall A.

What are the details of the poster presentation on bempikibart at EADV 2026?

The poster, titled “Preliminary Results for an Open-label Phase 2a Trial (SIGNAL-AA Part B) of Bempikibart, a Novel IL-7Rα Antibody in Patients with Severe or Very Severe Alopecia Areata (AA)” (Abstract AS-726), is part of the Biologics, immunotherapy, targeted therapy session on Wednesday, September 30, 2026, at 7:00 a.m. CEST / 1:00 a.m. EST in the Poster Area.

Who will present Q32 Bio’s bempikibart data at EADV 2026?

Both the late-breaking oral and the poster presentations will be delivered by Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation at Brigham and Women's Hospital, Harvard Medical School.

How can interested parties access the bempikibart EADV presentations after the meeting?

After the formal EADV presentations, the oral and poster materials will be made available in the “Presentations and Publications” section of Q32 Bio’s website, www.Q32Bio.com.

What is Q32 Bio’s broader focus in relation to bempikibart and alopecia areata?

Q32 Bio is a clinical-stage biotechnology company focused on therapies targeting regulators of the adaptive immune system. It is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody, for the treatment of alopecia areata in an ongoing Phase 2 program, and the company notes that IL-7 and TSLP pathways are implicated in several T cell-mediated autoimmune diseases.